Skip to main content
Terug
TARS logo

Tarsus Pharmaceuticals, Inc.

Datakwaliteit: 100%
TARS
NASDAQ Healthcare Biotechnology
€ 66,96
▲ € 3,81 (6,03%)
Marktkapitalisatie: 2,85B
Dagbereik
€ 64,35 € 67,76
52-Weeksbereik
€ 38,51 € 85,25
Volume
390.729
50D / 200D Gem.
€ 69,58 / € 62,35
Vorige Slotkoers
€ 63,15

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -42,9 0,2
P/B 8,3 3,0
ROE % -23,4 3,6
Net Margin % -14,7 3,8
Rev Growth 5Y % 67,7 9,9
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 89,00 +32.9%
Low: € 68,00 High: € 100,00
Forward WPA
-€ 0,63
Omzet Sch.
691,37M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 9,19
€ 8,89 – € 9,67
 1,33B 2
FY2029 € 6,99
€ 6,76 – € 7,35
 1,20B 2
FY2028 € 5,08
€ 3,10 – € 6,73
 1,06B 4

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-23 -€ 0,19 -€ 0,20 -5,3%
2025-11-04 -€ 0,35 -€ 0,30 +14,3%
2025-08-06 -€ 0,33 -€ 0,48 -45,5%
2025-05-01 -€ 0,69 -€ 0,64 +7,2%
2025-02-25 -€ 0,68 -€ 0,60 +11,8%
2024-11-13 -€ 0,94 -€ 0,61 +35,1%
2024-08-08 -€ 0,98 -€ 0,88 +10,2%
2024-05-08 -€ 1,15 -€ 1,01 +12,2%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 67,73% annually over 5 years — strong growth
Debt/Equity of 0,27 — conservative balance sheet
Negative free cash flow of -22,31M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 78,98%
Capital efficient — spends only 2,18% of revenue on capex

Groei

Revenue Growth (5Y)
67,73%
Revenue (1Y)146,71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-23,39%
ROIC-12,18%
Net Margin-14,72%
Op. Margin-15,72%

Veiligheid

Debt / Equity
0,27
Current Ratio3,85
Interest Coverage-7,94

Waardering

P/E Ratio
-42,90
Forward P/EN/A
P/B Ratio8,30
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 146,71% Revenue Growth (3Y) 408,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 67,73% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 451,36M Net Income (TTM) -66,42M
ROE -23,39% ROA -11,81%
Gross Margin 93,20% Operating Margin -15,72%
Net Margin -14,72% Free Cash Flow (TTM) -22,31M
ROIC -12,18% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,27 Current Ratio 3,85
Interest Coverage -7,94
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -42,90 Forward P/E N/A
P/B Ratio 8,30 P/S Ratio 6,31
PEG Ratio 1,07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 4,12 Fwd Earnings Yield N/A
FCF Yield -0,78%
Market Cap 2,85B Enterprise Value 2,76B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 451,36M 182,95M 17,45M 25,82M 57,03M
Net Income -66,42M -115,55M -135,89M -62,09M -13,83M
EPS (Diluted) -1,59 -3,07 -4,62 -2,52 -0,67
Gross Profit 420,68M 170,13M 15,85M 24,86M 54,95M
Operating Income -70,97M -120,57M -143,16M -62,71M -12,16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 562,16M 376,99M 265,49M 227,86M 178,91M
Total Liabilities 218,73M 152,46M 68,50M 34,96M 12,18M
Shareholders' Equity 343,43M 224,53M 196,99M 192,90M 166,73M
Total Debt 93,64M 72,45M 30,22M 20,21M 1,89M
Cash & Equivalents 183,64M 94,82M 224,95M 71,66M 171,33M
Current Assets 522,78M 356,71M 256,13M 225,38M 175,95M
Current Liabilities 135,70M 80,61M 36,94M 15,43M 11,48M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#7 of 148
76

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026